Timothy Paul Burkholder

This inventor holds 34 USPTO granted patents and 3 published patent applications, plus 12 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Eli Lilly and Company, Hoechst Marion Roussel, Merrell Pharmaceuticals, Inc.. Active years: 1995-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy Paul Burkholder. Retrieved from https://idiyas.com/inventor/timothy-paul-burkholder

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 3)

% Patents Active = 67.6

CIPO Patents = 12

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 4.9

ph-index = 6

Forward Citations = 130(Granted Patents)

Location History:

Fairfield, OH (US) (1995 - 1999)
Carmel, IN (US) (1999 - 2023)

Company Filing History:

16 out of 4,514

Eli Lilly and Company

patents

6 out of 236

Hoechst Marion Roussel

patents

6 out of 194

Merrell Pharmaceuticals, Inc.

patents

4. 4 out of 207

Aventis Pharmaceuticals Inc.

patents

5. 2 out of 455

Merrell Dow Pharmaceuticals

patents

Years Active: 1995-2023

Loading Chart...

Areas of Expertise:

IDH1 Inhibitors

Kinase Inhibitors

Serotonin Agonists

VEGF-R2 Inhibitors

GSK-3 Inhibitors

Piperazine Derivatives

Pyrrolidine Derivatives

Acyclic Carboxamide Derivatives

Benzofurylpiperazines

Purine Derivatives

Amino Pyrazole Compounds

Heterocyclic Compounds

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11649247 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2023-05-16),

2. 11629156 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2023-04-18),

3. 11001596 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2021-05-11),

4. 10696665 - Mutant IDH1 inhibitors (2020-06-30),

5. 10253041 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors (2019-04-09),

6. 9062050 - Inhibitor of JAK1 and JAK2 (2015-06-23),

7. 8436002 - AKT inhibitors (2013-05-07),

8. 8058425 - Purine derivatives as kinase inhibitors (2011-11-15),

9. 7897600 - Amino pyrazole compound (2011-03-01),

10. 7666879 - Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors (2010-02-23),

11. 7405305 - Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors (2008-07-29),

12. 7405299 - Compounds as pharmaceutical agents (2008-07-29),

13. 7045545 - Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists (2006-05-16),

14. 6967201 - Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists (2005-11-22),

15. 6881733 - Serotonergic benzofurans (2005-04-19),

Title: The Innovative Journey of Inventor Timothy Paul Burkholder

Introduction: Timothy Paul Burkholder, a talented inventor hailing from Carmel, IN, has made significant contributions to the field of medicine with his groundbreaking patents.

Latest Patents: Burkholder's latest patents revolve around 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors. These compounds and pharmaceutical compositions are aimed at treating IDH1 or IDH2 mutant cancer.

Career Highlights: With an impressive portfolio of 34 patents, Burkholder has showcased his ingenuity and expertise in the pharmaceutical industry. He has notably worked with renowned companies such as Eli Lilly and Company and Hoechst Marion Roussel.

Collaborations: Throughout his career, Burkholder has collaborated with esteemed professionals like Elizabeth M Kudlacz and George D Maynard. These partnerships have led to the development of innovative solutions in the medical field.

Conclusion: Timothy Paul Burkholder's inventive spirit and dedication to advancing cancer treatment have solidified his position as a leading figure in the world of pharmaceutical innovations. His contributions continue to inspire and pave the way for future breakthroughs in the industry.

Profile summary based on public USPTO records.